Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Angiography Suite Cone-Beam Computed Tomography Perfusion Imaging in Large Vessel Occlusion Thrombectomy Patients Using RAPID Software: A Pilot Study
Cerebrovascular Disease and Interventional Neurology
Cerebrovascular Disease and Interventional Neurology Posters (7:00 AM-5:00 PM)
049
We sought to evaluate the agreement between MDCTP and CBCTP projection datasets using RAPID software in patients undergoing MT.
Multidetector CT perfusion (MDCTP) is currently used for selecting late-window patients undergoing mechanical thrombectomy (MT). Direct transfer to angiosuite with Cone Beam CT perfusion (CBCTP) capabilities could reduce revascularization times. 

Anterior circulation large vessel occlusion (LVO) patients undergoing MDCTP and CBCTP were prospectively enrolled in a single arm interventional study. CBCTP images were acquired on an Artis Zee biplane system. CBCTP projection datasets were post-processed independently using a RAPID prototype. Core infarct was defined as CBF<45% in CBCTP images. Intraclass correlation coefficient (ICC) and Pearson (r) correlation were used for comparisons, and Bland-Altman analysis for agreement. Sensitivity analysis was also performed to evaluate the association between CBCTP images and the final infarct volume (FIV) on post-MT DWI-MRI sequences for patients with mTICI 2b-3.

Thirteen patients were included (male: 46%; median age 80 years, median NIHSS 19, LKW to groin puncture time:  302 minutes, MDCTP to CBCTP time: 47 minutes). Twelve patients underwent MT (one had spontaneous recanalization). Successful reperfusion was achieved in 10/12. There were no significant differences in median volumes of CBF (12ml IQR 7-50 vs 21.6ml IQR 0-91), Tmax>6s (184ml IQR 121-212 vs. 151ml IQR 76-192), and Tmax>10s (88ml IQR 40-133 vs. 71ml IQR 37-98) between MDCTP and CBCTP, respectively. We found an ICC of 0.89, 0.74, and 0.92 for CBF, Tmax>6s, and Tmax>10s, respectively. MDCTP correlated with CBCTP in CBF (r=0.91), Tmax>6s (r=0.74), and Tmax>10s (r=0.92). Bland-Altman analysis showed 92% agreement for CBF and Tmax>6s, and 100% for Tmax>10s. Sensitivity analysis showed good correlation (r=0.87, ρ=0.87) and ICC of 0.81 between FIV and CBCTP images.

Our results demonstrate a promising accuracy of CBCTP in evaluating infarct ischemic tissue in patients with LVO eligible for MT.

Authors/Disclosures
Darko E. Quispe Orozco, MD (TTUHSC-SOM, Lubbock; Neurology Dept.)
PRESENTER
Dr. Quispe Orozco has nothing to disclose.
No disclosure on file
Mudassir Farooqui, MD Dr. Farooqui has nothing to disclose.
Alan Mendez-Ruiz, MD (University of Iowa Hospitals and Clinics) Dr. Mendez-Ruiz has nothing to disclose.
Sameer Ansari Mr. Ansari has nothing to disclose.
No disclosure on file
Sudeepta Dandapat, MD (Aurora Neurosciences Innovation Institute) Dr. Dandapat has nothing to disclose.
Kaustubh S. Limaye, MD (Indiana University School of Medicine) Dr. Limaye has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Scientia Vascular.
Edgar Samaniego, MD, FÂé¶¹´«Ã½Ó³»­ (University of Iowa Hospital and Clinics) Dr. Samaniego has received personal compensation for serving as an employee of University of Iowa. Dr. Samaniego has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Terumo Neuro. Dr. Samaniego has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Rapid Medical. Dr. Samaniego has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for J&J Neuro. Dr. Samaniego has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Metronic. Dr. Samaniego has received personal compensation in the range of $0-$499 for serving as a Consultant for iSchemaView. Dr. Samaniego has received personal compensation in the range of $0-$499 for serving as an officer or member of the Board of Directors for Society of Neurointerventional Surgery. Dr. Samaniego has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Journal of Neurointerventional Surgery.
Colin Derdeyn, MD (University of Iowa Hospitals & Clinics) The institution of Dr. Derdeyn has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Penumbra. The institution of Dr. Derdeyn has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NoNO. The institution of Dr. Derdeyn has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Silk Road. Dr. Derdeyn has stock in Pulse Therapeutics. Dr. Derdeyn has received publishing royalties from a publication relating to health care.
Nils Petersen, MD, FÂé¶¹´«Ã½Ó³»­ (Yale University) The institution of Dr. Petersen has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Silkroad Medical. Dr. Petersen has received research support from NIH.
Santiago Ortega Gutierrez, MD (University of Iowa) Dr. Ortega Gutierrez has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for stryker. Dr. Ortega Gutierrez has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for medtronic. Dr. Ortega Gutierrez has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Medtronic. The institution of Dr. Ortega Gutierrez has received research support from stryker. The institution of Dr. Ortega Gutierrez has received research support from Medtronic. The institution of Dr. Ortega Gutierrez has received research support from Methinks. The institution of Dr. Ortega Gutierrez has received research support from NIH. The institution of Dr. Ortega Gutierrez has received research support from PCORI.